pharma · Multiple Myeloma · Not applicable - Healthy volonteers · GPCR
Structure Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker GPCR. Primary therapeutic focus areas include Multiple Myeloma, Not applicable - Healthy volonteer
Phase 2 · small molecule · Obesity
Aleniglipron (GSBR-1290-09) is a small-molecule investigational therapeutic developed by Structure Therapeutics for the treatment of obesity. The program is currently in Phase 2 development, with a completed trial status as of the latest milestone dated 28 April 2026. The specific mechanism of action and molecular targ
Internal code GSBR-1290-09
Aleniglipron (GSBR-1290-09) is a small-molecule investigational therapeutic developed by Structure Therapeutics for the treatment of obesity. The program is currently in Phase 2 development, with a completed trial status as of the latest milestone dated 28 April 2026. The specific mechanism of action and molecular target have not yet been disclosed. Structure Therapeutics is advancing aleniglipron as part of its obesity pipeline, positioning the candidate within a competitive landscape that includes both approved pharmacotherapies and emerging GLP-1 receptor agonists. The Phase 2 trial (NCT06703021) represents a key clinical milestone in the candidate's development trajectory. No regulatory approvals, partnerships, or peak sales projections have been disclosed at this time. The program's completion of Phase 2 testing suggests progression toward potential Phase 3 initiation, though next-stage timelines remain undisclosed.
Obesity represents a significant unmet medical need with substantial commercial opportunity. The global obesity treatment market has expanded dramatically following the clinical and commercial success of GLP-1 receptor agonists such as semaglutide and tirzepatide, which have demonstrated efficacy in weight reduction and metabolic improvement. Aleniglipron enters a market characterized by growing patient demand, expanding reimbursement coverage, and increasing physician adoption of pharmacological interventions for chronic weight management. The competitive landscape includes both established small-molecule therapies and newer biologic agents. Structure Therapeutics' small-molecule approach may offer advantages in oral bioavailability, manufacturing scalability, and patient convenience compared to injectable competitors. The Phase 2 completion milestone indicates the program has generated clinical efficacy and safety data sufficient to advance development. Success in obesity treatment could position aleniglipron as a significant revenue contributor, given the large addressable patient population and premium pricing observed in the obesity therapeutic class. The program's advancement reflects Structure Therapeutics' strategic commitment to metabolic disease, an area of intense pharmaceutical innovation and investment.
Drug Class: Small-molecule investigational therapeutic
Modality: Small molecule
Indication: Obesity
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Not yet disclosed
Sponsor: Structure Therapeutics
Development Status: Phase 2 (completed)
Related Therapies: The obesity treatment landscape includes GLP-1 receptor agonists (semaglutide, tirzepatide), combination therapies (naltrexone/bupropion), and other small-molecule approaches. Aleniglipron's specific mechanism and target differentiation from existing therapies remain undisclosed.
Patent Status: Not yet disclosed
First Approval: Not applicable; candidate remains in clinical development
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 trial completed
GSBR-1290-09 Phase 2 trial (NCT06703021) marked as completed; next milestone and regulatory pathway not yet disclosed.
The obesity treatment market includes multiple approved small-molecule and biologic therapies. Approved competitors listed in the competitive set include simvastatin (Hospital Authority, Hong Kong), pioglitazone (Takeda), and combination agents such as candesartan/hydrochlorothiazide (Takeda). The competitive landscape also references Mounjaro (tirzepatide injection) and Mysimba (naltrexone/bupropion combination), both approved for obesity. Semaglutide formulations represent a major competitive standard. The inclusion of esomeprazole, ibuprofen, and other non-obesity-specific agents in the competitive dataset suggests potential data quality issues in the source material. Aleniglipron's small-molecule approach may differentiate from injectable GLP-1 agonists through oral administration and potentially distinct mechanism of action, though the specific target and mechanism remain undisclosed. Structure Therapeutics' competitive positioning will depend on efficacy, safety, tolerability, and pharmacokinetic advantages relative to established therapies and other pipeline candidates.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Simvastatin | Hospital Authority, Hong Kong | small_molecule | approved |
| Pioglitazone | Takeda | small_molecule | approved |
| Semaglutide B 3.0 mg/ml PDS290 | Disc Medicine | small_molecule | approved |
| Mounjaro solution for injection in pre-filled... for Obesity | The George Institute | small_molecule | approved |
| ESOMEPRAZOLE, ESOMEPRAZOLE | Fondazione Telethon ETS | small_molecule | approved |
| Candesartan and Hydrochlorothiazide | Takeda | small_molecule | approved |
| NN9838-4968 | NovoThirteen | small_molecule | approved |
| Intravenous Ibuprofen | CUMBERLAND PHARMACEUTICALS INC | small_molecule | approved |
| NN9536-7752 | NovoThirteen | small_molecule | approved |
| ANGELO | The George Institute | small_molecule | approved |
| Mysimba 8 mg/90 mg prolonged-release tablets | Disc Medicine | small_molecule | approved |
| RIMEGEPANT , Capsaicin | Disc Medicine | small_molecule | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed. Aleniglipron remains in Phase 2 clinical development with no regulatory submissions or approvals reported.
EMA Status: Not yet disclosed.
PMDA (Japan) Status: Not yet disclosed.
NMPA (China) Status: Not yet disclosed.
Clinical Trial Registration: NCT06703021 is the primary trial identifier for the Phase 2 program. Additional historical NCT identifiers referenced in the placebo drug record (NCT00076336, NCT00415194, NCT00525798, NCT00591084, NCT00741936, NCT00901901, NCT00940602, NCT01136239, NCT01317849, NCT01325571) appear to relate to prior research or comparator studies rather than aleniglipron development.
Regulatory pathway, breakthrough designation status, and timelines for potential Phase 3 initiation or regulatory submissions have not been disclosed.
Aleniglipron (GSBR-1290-09) is an investigational small-molecule therapeutic in Phase 2 development for the treatment of obesity, currently being developed by Structure Therapeutics.
No. Aleniglipron remains in Phase 2 clinical development and has not been approved by the FDA or other regulatory authorities. No regulatory submissions have been disclosed.
The mechanism of action and molecular target of aleniglipron have not yet been disclosed by Structure Therapeutics.
Aleniglipron is being developed by Structure Therapeutics. No manufacturing partners or agreements have been disclosed.
Aleniglipron is in Phase 2 development. The Phase 2 trial (NCT06703021) was completed as of 28 April 2026, but results have not yet been disclosed.
The primary trial is NCT06703021, a Phase 2 randomized controlled trial comparing aleniglipron to placebo in obesity. Trial results have not yet been reported.
The route of administration (oral, injectable, etc.) has not yet been disclosed.
The specific molecular target has not been disclosed by Structure Therapeutics.
Aleniglipron is a small-molecule investigational therapeutic, distinguishing it from biologic approaches such as GLP-1 receptor agonists.
No partnership or licensing agreements have been disclosed for aleniglipron.
Aleniglipron competes in the obesity treatment market with approved therapies including GLP-1 receptor agonists (semaglutide, tirzepatide), combination agents (naltrexone/bupropion), and other small-molecule approaches.
No approval timeline has been disclosed. The program is in Phase 2; typical development timelines for obesity therapeutics range from 3-5+ years to regulatory approval.
Peak sales projections have not been disclosed by Structure Therapeutics or industry analysts.
The internal development code is GSBR-1290-09.
The primary Phase 2 trial is registered as NCT06703021 on ClinicalTrials.gov.
As of the latest available information (28 April 2026), Phase 2 results have not been publicly disclosed, though the trial is marked as completed.
aleniglipron or placebo → Drug → Target → Indication → Company → Trials → Competitors
Development Status: Completion of Phase 2 testing represents a significant milestone, indicating that aleniglipron has generated sufficient efficacy and safety data to support advancement. The absence of disclosed results or next-milestone timelines suggests Structure Therapeutics is evaluating data before announcing Phase 3 plans or regulatory strategy.
Competitive Positioning: Aleniglipron enters an obesity market dominated by GLP-1 receptor agonists with proven efficacy and established market penetration. Success will require differentiation through superior efficacy, improved tolerability, oral bioavailability, or cost advantages. The undisclosed mechanism of action limits assessment of competitive differentiation at this time.
Strategic Implications: Structure Therapeutics' investment in obesity reflects market recognition of the therapeutic class's commercial potential and unmet medical need. The small-molecule approach suggests the company is pursuing an alternative to injectable biologic competitors, potentially targeting patients who prefer oral administration or have contraindications to GLP-1 agonists.
Future Catalysts: Key upcoming milestones include announcement of Phase 2 results, disclosure of mechanism of action and molecular target, initiation of Phase 3 trials, and regulatory interactions with FDA or other authorities. Commercial success will depend on efficacy margins relative to standard-of-care GLP-1 agonists and payer acceptance.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.